Asprosin, a novel glucogenic adipokine implicated in type 2 diabetes mellitus.

Diao, Hongcui; Li, Xue; Xu, Yeqiu; Xing, Xiuli; Pang, Shuguang

Diao, Hongcui; Li, Xue; Xu, Yeqiu; Xing, Xiuli; Pang, Shuguang.

Affiliation

Diao H; Department of Endocrinology, Jinan Central Hospital, Shandong University, Jinan, China.
Li X; Department of Infectious Diseases, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Xu Y; Department of Eye, Oral & Plastic Surgery, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Xing X; Department of Endocrinology, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Pang S; Department of Endocrinology, Jinan Central Hospital, Shandong University, Jinan, China; Department of Endocrinology, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, China. Electronic address: shuguangpang@163.com.

J Diabetes Complications ; 37(11): 108614, 2023 11.

Article de En | MEDLINE | ID: mdl-37769508

Sujet(s)
Mots clés

Asprosin; Blood glucose; Diabetes mellitus; FBN1; Insulin

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Insulinorésistance / Hormones peptidiques / Diabète de type 2 Limites: Humans Langue: En Journal: J Diabetes Complications Sujet du journal: ENDOCRINOLOGIA Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google